Epidermolysis Bullosa

Dermatology·MeSH: Epidermolysis Bullosa

Prevalence

0.5 / 100K

20 drugs in development·14 companies·4 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
d-fi	Ligand Pharmaceuticals Incorporated (LGND)
vyjuvek	Krystal Biotech, Inc. (KRYS)
zevaskyn	ABEONA THERAPEUTICS INC. (ABEO)

Phase 3(10)

Drug	Company
cordstrom	Inmune Bio, Inc. (INMB)
d-fi	XOMA Royalty Corporation (XOMA)
d-fi	Castle Biosciences Inc. (CSTL)
D-Fi	Crinetics Pharmaceuticals, Inc. (CRNX)
fcx-007	Castle Biosciences Inc. (CSTL)
kb803	Krystal Biotech, Inc. (KRYS)
rgn-137	REGENERX BIOPHARMACEUTICALS INC (RGRX)
rigosertib	TRAWS PHARMA, INC. (ONTX)
SD-101 dermal cream	AMICUS THERAPEUTICS, INC. (FOLD)
SD-101-6.0 cream	AMICUS THERAPEUTICS, INC. (FOLD)

Phase 2(2)

Drug	Company
inm-755	InMed Pharmaceuticals Inc. (INM)
Vehicle	AMICUS THERAPEUTICS, INC. (FOLD)

BLA Filed(2)

Drug	Company
prademagene zamikeracel (pz-cel)	ABEONA THERAPEUTICS INC. (ABEO)
pz-cel	ABEONA THERAPEUTICS INC. (ABEO)

Phase 1/Phase 2(2)

Drug	Company
agle-102	AGILE THERAPEUTICS INC (AGRX)
fcx-007	Fibrocell Science, Inc. (FCSC)

Phase 2/Phase 3(1)

Drug	Company
qrx004	Quoin Pharmaceuticals, Ltd. (QNRX)

BioSniper tracks 20 drugs in development for Epidermolysis Bullosa across 14 companies.

There are 4 clinical trials targeting Epidermolysis Bullosa tracked by BioSniper.

The estimated prevalence of Epidermolysis Bullosa is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.